Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion

In early May 2026, Arcutis Biotherapeutics reported first-quarter revenue of US$105.4 million, reduced its net loss to US$11.3 million, and reaffirmed full-year 2026 net product revenue guidance of US$480 million to US$495 million. The company also filed an sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months with mild to moderate atopic dermatitis, potentially widening its addressable pediatric market with a steroid-free option in a segment that currently has only one other approved non-steroidal choice. Now we’ll examine how this combination of stronger quarterly results and reaffirmed revenue guidance may influence Arcutis’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.

Arcutis Biotherapeutics Investment Narrative Recap

To own Arcutis, you need to believe that the ZORYVE franchise can support a sustainable, eventually profitable dermatology business despite its concentration risk. The stronger first quarter and reaffirmed 2026 revenue outlook support the near term revenue catalyst, but do not remove key risks around dependence on one product family and the possibility that high R&D and SG&A spending could prolong operating losses.

Among the recent news, the sNDA to extend ZORYVE cream 0.05% to infants as young as 3 months stands out, because it directly speaks to the franchise’s growth potential in atopic dermatitis. While the filing itself does not change current financials, it ties into the central catalyst of expanding ZORYVE’s addressable pediatric market with a steroid free option in a population where approved non steroidal choices are limited.

Yet beneath the improved quarterly numbers and pipeline news, investors should still be aware of the risk that...

Read the full narrative on Arcutis Biotherapeutics (it's free!)

Arcutis Biotherapeutics’ narrative projects $784.6 million revenue and $266.1 million earnings by 2029.

Uncover how Arcutis Biotherapeutics' forecasts yield a $34.75 fair value, a 68% upside to its current price.

Exploring Other PerspectivesARQT 1-Year Stock Price Chart

Three fair value estimates from the Simply Wall St Community span roughly US$34.75 to about US$81.45 per share, highlighting a wide spread in expectations. Against that backdrop, the reaffirmed 2026 revenue guidance and ZORYVE focused growth story show why it can help to compare differing views before deciding how Arcutis’s concentration risk fits into your portfolio.

Explore 3 other fair value estimates on Arcutis Biotherapeutics - why the stock might be worth just $34.75!

Story Continues

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision. Our free Arcutis Biotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcutis Biotherapeutics' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ARQT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments